文献速递湿疹皮炎与荨麻疹

度普利尤单抗治疗6-11岁儿童特应性皮炎的有效性与安全性:法国多中心回顾性真实世界队列数据

Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-08-04

法国多中心回顾性队列纳入80例6-11岁首次接受度普利尤单抗治疗的中重度特应性皮炎患儿,治疗3个月后SCORAD和IGA均显著下降,结膜炎发生率11.3%,面部红斑3例,注射部位反应17.5%,停药6.3%,61.2%患儿不符合Ⅲ期临床试验入组标准。真实世界数据证实度普利尤单抗有效且安全,但注射给药可能成为该年龄组的障碍。

要点

  • 治疗3个月SCORAD由53.9±18.5降至21.8±13.8,IGA由3.5±0.7降至1.3±0.8,均P<0.0001。
  • 结膜炎11.3%(9/80),度普利尤单抗面部红斑3例,注射部位反应17.5%(14/80),停药6.3%(5/80)。
  • 61.2%(49/80)患儿不符合Ⅲ期临床试验入组标准,真实世界人群与试验人群存在差异。

核心结论

  • 真实世界数据证实度普利尤单抗对儿童中重度特应性皮炎有效且安全,并扩展至出汗不良和特应性痒疹,但度普利尤单抗面部红斑和结膜炎频率较低。
  • 注射给药形式可能成为该年龄组的障碍。

研究设计与样本

  • 法国多中心回顾性真实世界队列研究,纳入80例6-11岁首次接受度普利尤单抗治疗的患儿。
  • 主要终点为治疗3个月后SCORAD变化,次要终点包括3个月IGA变化、SCORAD50和SCORAD75比例、不良事件描述及不符合Ⅲ期临床试验入组标准的患儿比例。

主要发现

  • 治疗3个月后SCORAD显著下降(均值21.8±13.8 vs 53.9±18.5,P<0.0001)。
  • 治疗3个月后IGA显著下降(1.3±0.8 vs 3.5±0.7,P<0.0001)。
  • 结膜炎发生率为11.3%(n=9/80),3例出现度普利尤单抗面部红斑(DFR)。
  • 注射部位反应报告率为17.5%(n=14/80),6.3%(n=5/80)停药。
  • 61.2%(n=49/80)患儿不符合Ⅲ期临床试验入组标准。

临床怎么用

  • 作者认为真实世界数据证实度普利尤单抗对儿童中重度特应性皮炎有效且安全,并扩展至出汗不良和特应性痒疹。
  • 作者指出注射给药形式可能成为该年龄组的障碍。

局限性

  • 无对照组。
  • 研究为基于法国多中心队列患者病历信息的真实世界研究,使用患者报告特征和缺失信息,不能排除报告偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Dupilumab is the first biotherapy available for the treatment of moderate-to-severe childhood atopic dermatitis (AD). OBJECTIVE: The aim of this study was to evaluate the effectiveness and safety of dupilumab in daily practice. METHODS: Patients aged 6-11, who had received a first dose of dupilumab, were included in this multicentre retrospective cohort study. The primary endpoint was change in SCORAD after 3 months of treatment. Secondary endpoints were change in IGA score at 3 months, proportion of patients with SCORAD50 and SCORAD75, description of adverse events and proportion of children in our cohort who would be excluded from pivotal phase 3 clinical trial. RESULTS: Eighty patients were included. After 3 months of treatment, there was a significant decrease in SCORAD (mean: 21.8 ± 13.8 vs 53.9 ± 18.5; P < 0.0001) and IGA (1.3 ± 0.8 vs 3.5 ± 0.7; P < 0.0001). Conjunctivitis was observed in 11.3% (n = 9/80); three patients experienced dupilumab facial redness (DFR); 17.5% (n = 14/80) reported injection site reactions; 6.3% (n = 5/80) discontinued treatment. 61.2% (n = 49/80) children were ineligible in the phase 3 trial. LIMITATIONS: There is no control group. Because it was a real life study based on information from patient medical records in a French multicentre cohort, we cannot rule out the presence of reporting bias generated by the use of patient reported characteristics and missing information. CONCLUSION: These real-life data confirm the efficacy and safety of dupilumab in children with moderate to severe AD extended to dyshidrosis and atopic prurigo, but it also revealed a lower frequency of DFR and conjunctivitis. However, administration in injectable form may be a barrier in this age group.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Lasek A, Bellon N, Mallet S, et al. Effectiveness and safety of dupilumab in the treatment of atopic dermatitis in children (6-11 years): data from a French multicentre retrospective cohort in daily practice. J Eur Acad Dermatol Venereol. 2022. PMID: 35854650. doi:10.1111/jdv.18450

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。